At present, numerous VEGFR-2 inhibitors have been created or are in various stages of development; sorafenib, cabozantinib, and sunitinib are widely used in clinical cancer treatment, But still, new inhibitors are needed [12]. The gene discussed is KDR; the disease is cancer.